The Lancet HIV in conversation with podcast

Implementation of long-acting injectable cabotegravir for PrEP in Brazil with Beatriz Grinsztejn

0:00
25:19
Rewind 15 seconds
Fast Forward 15 seconds

Daily oral PrEP is highly effective, but taking a pill consistently can be challenging. Could long-acting injectable cabotegravir help close gaps in HIV prevention? What would it take to make it available through Brazil’s public health system? In this episode, the authors discuss the ImPrEP CAB Brasil study, which evaluated same-day access to injectable PrEP across six Brazilian cities, explore what the study found about PrEP coverage, participant choice, and delivering CAB-LA in routine care, as well as the questions that remain for equitable access and scale-up.

Click here to read the full article:

https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00201-8/fulltext

More episodes from "The Lancet HIV in conversation with"